Biotechnology & Life Sciences Global On demand · 24-48h

Global Coccidiosis Vaccines Market Strategic Research Report

Global Coccidiosis Vaccines Market Strategic Research Report
$3,500 USD
Market Research Reports
Strategic Research Report
Global Coccidiosis Vaccines Market
$1722025
5%CAGR
2032Forecast
Market Research Reports · Global
Market Research Reports Intelligence Series

By Type: Attenuated Vaccines, Non-attenuated Vaccines

By Application: Poultry, Rabbit, Others

Regional Forecast: Asia Pacific, Latin America, MEA, Europe, North America

Key Players: MSD Animal Health, Boehringer Ingelheim, HIPRA, Bioproperties, Huvepharma, Nisseiken, Biopharm, Ceva Santé Animale, Vaxxinova, Foshan Standard Biotech, Qilu Qingda Bio-Pharmaceutical, Skystar Bio-pharm, Hlinte, Guangdong Winsun Bio-pharmaceutical

Region: Global
Formats: PDF, Excel, Word & PowerPoint
Base year: 2025 · forecast to 2032
Length: 124 pages
Market size 2025
$172
Million USD
Forecast CAGR
5%
2025-2032
Forecast 2032
$242
Projected
영역들
5
Asia Pacific · Latin America · MEA · Europe · North America

개요

Scope of the Report

The global Coccidiosis Vaccines market size is predicted to grow from US$ 172 million in 2025 to US$ 241 million in 2032; it is expected to grow at a CAGR of 5.0% from 2026 to 2032.

Coccidiosis vaccines are biological preparations aimed at preventing coccidiosis, a parasitic disease primarily affecting livestock and poultry, particularly chickens. This disease is caused by various species of protozoan parasites from the genus Eimeria, which infect the intestinal lining, leading to symptoms such as diarrhea, weight loss, and decreased feed efficiency. Coccidiosis vaccines typically contain live attenuated or killed strains of Eimeria parasites, which stimulate the host's immune system to develop protective immunity against future infections.

Coccidiosis is one of the most common parasitic diseases in the poultry industry, primarily caused by Eimeria species. This disease poses a significant threat to poultry health and can lead to a notable decrease in production performance, even resulting in death. Traditionally, the poultry industry has relied on anticoccidial drugs for prevention and treatment, but with the increasing problem of drug resistance, the over-reliance on anticoccidial medications is gradually being challenged. As a result, coccidiosis vaccines have become an important alternative to drug treatments.

The vaccine works by simulating a coccidial infection, triggering an immune response in the poultry's system, thereby enhancing immunity against future infections. Unlike drug treatments, vaccines effectively reduce the dependence on antibiotics, help curb the development of resistance, and promote a more sustainable and environmentally friendly poultry industry. The use of coccidiosis vaccines not only reduces the incidence and mortality of infections in poultry flocks but also improves production performance, such as weight gain in broilers and egg production in layers.

In recent years, with continuous innovation in vaccine technology, the types and effectiveness of coccidiosis vaccines have significantly improved. There are now many types of coccidiosis vaccines on the market, including attenuated live vaccines, inactivated vaccines, and recombinant and multivalent vaccines currently under development. These new-generation vaccines can target different species of Eimeria and offer stronger immune protection.

The demand for coccidiosis vaccines has gradually increased in recent years, mainly due to the rising consumer demand for antibiotic-free food and increased awareness of animal welfare and environmental protection. With the global trend towards larger-scale and more intensive poultry farming, the use of vaccines has become a key method for ensuring the health and sustainable development of poultry production.

Especially in the European and American markets, an increasing number of poultry farms are gradually eliminating anticoccidial drugs and turning to vaccines for prevention and treatment. This shift has contributed to the rapid growth of the vaccine market. In the Asia-Pacific region, particularly in countries such as China, India, and Southeast Asia, with the rapid development of poultry farming, the demand for coccidiosis vaccines is also increasing. More countries and regions are beginning to implement strict drug residue regulations, which has further driven the use of vaccines as an alternative solution.

Key Questions Addressed in this Report

What is the 10-year outlook for the global Coccidiosis Vaccines market?

What factors are driving Coccidiosis Vaccines market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Coccidiosis Vaccines market opportunities vary by end market size?

How does Coccidiosis Vaccines break out by Type, by Application?

This report presents a comprehensive overview of the global Coccidiosis Vaccines market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

  • Attenuated Vaccines
  • Non-attenuated Vaccines

Segment by Application

  • Poultry
  • Rabbit
  • Others

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Coccidiosis Vaccines market:

  • Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
  • Distributors, channel partners and end users in Poultry, Rabbit, Others evaluating demand and sourcing options
  • Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
  • Government agencies, industry associations and research institutions tracking industry developments and policy impact

Market snapshot

Global Coccidiosis Vaccines Market Strategic Research Report snapshot, 2025–2032

Source: Market Research Reports
Market size CAGR 5%
Regional growth momentum
Market share by segment
Key metrics
Base value
$172
2025
Forecast
$242
2032
CAGR
5%
2025–2032
영역들
5
global
Key companies
MSD Animal HealthBoehringer IngelheimHIPRABiopropertiesHuvepharmaNisseikenBiopharmCeva Santé Animale
© MarketResearchReports.comDisclaimer: The actual data may vary in the final report which undergoes verification check post order confirmation.

Segments covered in this report

By Type
Attenuated VaccinesNon-attenuated Vaccines
By Application
PoultryRabbitOthers

Table of contents

Click a chapter to expand
01Executive Summary
02Industry Overview & Forecast
  • 2.1.1 Market Definition and Scope
  • 2.1.2 Market Size and Growth Forecast
  • 2.1.3 Volume Analysis
  • 2.1.4 Segment Outlook by Type
  • 2.1.5 Segment Outlook by Application
  • 2.1.6 Regional Outlook
  • 2.1.7 Structural Developments Shaping the Forecast
  • 2.1.8 Forecast Risks and Sensitivities
03Market Segmentation by Type
  • 3.1 Market Segmentation by Type
  • 3.1.1 Market by Type Overview
  • 3.1.2 Attenuated Vaccines
  • 3.1.3 Non-attenuated Vaccines
  • 3.1.4 Volume Analysis
04Market Segmentation by Application
  • 4.1 Market Segmentation by Application
  • 4.1.1 Market by Application Overview
  • 4.1.2 Poultry
  • 4.1.3 Rabbit
  • 4.1.4 Others
  • 4.1.5 Volume Analysis
05Regional Market Forecast
  • Asia Pacific
  • North America
  • Europe
  • Middle East & Africa
  • Latin America
06Country-Level Market Forecast
  • 6.1 Asia Pacific
  • 6.1.1 China
  • 6.1.2 Japan
  • 6.1.3 Korea
  • 6.1.4 Southeast Asia
  • 6.1.5 India
  • 6.1.6 Australia
  • 6.1.7 Rest of Asia Pacific
  • 6.2 North America
  • 6.2.1 United States
  • 6.2.2 Canada
  • 6.2.3 Mexico
  • 6.2.4 Rest of North America
  • 6.3 Europe
  • 6.3.1 Germany
  • 6.3.2 France
  • 6.3.3 UK
  • 6.3.4 Italy
  • 6.3.5 Russia
  • 6.3.6 Rest of Europe
  • 6.4 Middle East & Africa
  • 6.4.1 Egypt
  • 6.4.2 South Africa
  • 6.4.3 Israel
  • 6.4.4 Turkey
  • 6.4.5 GCC Countries
  • 6.4.6 Rest of Middle East & Africa
  • 6.5 Latin America
  • 6.5.1 Brazil
  • 6.5.2 Rest of Latin America
07Growth Drivers & Inhibitors
  • 7.1 Growth Drivers & Inhibitors
  • 7.1.1 Section Overview
  • 7.1.2 Growth Drivers
  • 7.1.3 Growth Inhibitors
  • 7.1.4 Driver and Inhibitor Impact Assessment
  • 7.1.5 Analyst Perspective
08Key Company Profiles
  • 8.1 MSD Animal Health
  • 8.1.1 Company Overview
  • 8.1.2 Key Products & Segments
  • 8.1.3 Financial Performance (2023–2025)
  • 8.1.4 Business Strategy
  • 8.1.5 SWOT Analysis
  • 8.1.6 Strategic Implications (2026–2032)
  • 8.2 Boehringer Ingelheim
  • 8.2.1 Company Overview
  • 8.2.2 Key Products & Segments
  • 8.2.3 Financial Performance (2023–2025)
  • 8.2.4 Business Strategy
  • 8.2.5 SWOT Analysis
  • 8.2.6 Strategic Implications (2026–2032)
  • 8.3 HIPRA
  • 8.3.1 Company Overview
  • 8.3.2 Key Products & Segments
  • 8.3.3 Financial Performance (2023–2025)
  • 8.3.4 Business Strategy
  • 8.3.5 SWOT Analysis
  • 8.3.6 Strategic Implications (2026–2032)
  • 8.4 Bioproperties
  • 8.4.1 Company Overview
  • 8.4.2 Key Products & Segments
  • 8.4.3 Financial Performance (2023–2025)
  • 8.4.4 Business Strategy
  • 8.4.5 SWOT Analysis
  • 8.4.6 Strategic Implications (2026–2032)
  • 8.5 Huvepharma
  • 8.5.1 Company Overview
  • 8.5.2 Key Products & Segments
  • 8.5.3 Financial Performance (2023–2025)
  • 8.5.4 Business Strategy
  • 8.5.5 SWOT Analysis
  • 8.5.6 Strategic Implications (2026–2032)
  • 8.6 Nisseiken
  • 8.6.1 Company Overview
  • 8.6.2 Key Products & Segments
  • 8.6.3 Financial Performance (2023–2025)
  • 8.6.4 Business Strategy
  • 8.6.5 SWOT Analysis
  • 8.6.6 Strategic Implications (2026–2032)
  • 8.7 Biopharm
  • 8.7.1 Company Overview
  • 8.7.2 Key Products & Segments
  • 8.7.3 Financial Performance (2023–2025)
  • 8.7.4 Business Strategy
  • 8.7.5 SWOT Analysis
  • 8.7.6 Strategic Implications (2026–2032)
  • 8.8 Ceva Santé Animale
  • 8.8.1 Company Overview
  • 8.8.2 Key Products & Segments
  • 8.8.3 Financial Performance (2023–2025)
  • 8.8.4 Business Strategy
  • 8.8.5 SWOT Analysis
  • 8.8.6 Strategic Implications (2026–2032)
  • 8.9 Vaxxinova
  • 8.9.1 Company Overview
  • 8.9.2 Key Products & Segments
  • 8.9.3 Financial Performance (2023–2025)
  • 8.9.4 Business Strategy
  • 8.9.5 SWOT Analysis
  • 8.9.6 Strategic Implications (2026–2032)
  • 8.10 Foshan Standard Biotech
  • 8.10.1 Company Overview
  • 8.10.2 Key Products & Segments
  • 8.10.3 Financial Performance (2023–2025)
  • 8.10.4 Business Strategy
  • 8.10.5 SWOT Analysis
  • 8.10.6 Strategic Implications (2026–2032)
  • 8.11 Qilu Qingda Bio-Pharmaceutical
  • 8.11.1 Company Overview
  • 8.11.2 Key Products & Segments
  • 8.11.3 Financial Performance (2023–2025)
  • 8.11.4 Business Strategy
  • 8.11.5 SWOT Analysis
  • 8.11.6 Strategic Implications (2026–2032)
  • 8.12 Skystar Bio-pharm
  • 8.12.1 Company Overview
  • 8.12.2 Key Products & Segments
  • 8.12.3 Financial Performance (2023–2025)
  • 8.12.4 Business Strategy
  • 8.12.5 SWOT Analysis
  • 8.12.6 Strategic Implications (2026–2032)
  • 8.13 Hlinte
  • 8.13.1 Company Overview
  • 8.13.2 Key Products & Segments
  • 8.13.3 Financial Performance (2023–2025)
  • 8.13.4 Business Strategy
  • 8.13.5 SWOT Analysis
  • 8.13.6 Strategic Implications (2026–2032)
  • 8.14 Guangdong Winsun Bio-pharmaceutical
  • 8.14.1 Company Overview
  • 8.14.2 Key Products & Segments
  • 8.14.3 Financial Performance (2023–2025)
  • 8.14.4 Business Strategy
  • 8.14.5 SWOT Analysis
  • 8.14.6 Strategic Implications (2026–2032)
09Competitive Landscape
  • 9.1 Competitive Landscape Overview
  • 9.2 Competitive Intensity Assessment
  • 9.3 Key Player Strategies & Positioning
  • 9.4 Competitive Dynamics & Strategic Outlook
  • 9.4.1 Emerging Competitive Threats
  • 9.4.2 Consolidation vs. Fragmentation Outlook
  • 9.4.3 Competitive Response Matrix
  • 9.4.4 Strategic Recommendations, 2026–2032
10Porter's Five Forces Analysis
  • 10.1 Threat of New Entrants
  • 10.2 Bargaining Power of Buyers
  • 10.3 Bargaining Power of Suppliers
  • 10.4 Threat of Substitutes
  • 10.5 Competitive Rivalry
11PESTLE Analysis
  • 11.1 Political
  • 11.2 Economic
  • 11.3 Social and Demographic
  • 11.4 Technological
  • 11.5 Legal and Regulatory
  • 11.6 Environmental
  • 11.7 Strategic Implications of the PESTLE Assessment
12SWOT Analysis
13Future Trends & Outlook
  • 13.1 Future Trends & Outlook
  • 13.1.1 Trend Summary and Commercial Maturity Assessment
  • 13.1.2 Technology and Innovation Trends
  • 13.1.3 Long-Term Market Outlook
  • 13.1.4 Investment & M&A Activity Outlook
  • 13.1.5 Overall Outlook Assessment

Frequently asked questions

How big is the global Coccidiosis Vaccines market?
The global Coccidiosis Vaccines market is estimated at US$ 172 million in 2025 (base year) and is projected to reach US$ 241 million by 2032.
How fast is the Coccidiosis Vaccines market expected to grow?
The market is expected to grow at a CAGR of 5.0% from 2026 to 2032, expanding from US$ 172 million in 2025 to US$ 241 million in 2032, roughly 1.4 times its base-year value.
What does the Coccidiosis Vaccines market cover?
Coccidiosis vaccines are biological preparations aimed at preventing coccidiosis, a parasitic disease primarily affecting livestock and poultry, particularly chickens. This disease is caused by various species of protozoan parasites from the genus Eimeria, which infect the intestinal lining, leading to symptoms such as diarrhea, weight loss, and decreased feed efficiency.
How is the Coccidiosis Vaccines market segmented by type?
By type, the market is segmented into Attenuated Vaccines and Non-attenuated Vaccines.
What are the key applications of Coccidiosis Vaccines?
Key applications covered include Poultry, Rabbit and Others.
Which companies are profiled in the Coccidiosis Vaccines market report?
Key players profiled include MSD Animal Health, Boehringer Ingelheim, HIPRA, Bioproperties, Huvepharma, Nisseiken, Biopharm and Ceva Santé Animale, among 14 companies covered in total.
What geographies does the Coccidiosis Vaccines market analysis include?
The market is analysed across Asia Pacific, North America, Europe, Middle East & Africa and Latin America, with 20 country-level markets including China, Japan, United States, Canada, Germany, France, Egypt and South Africa.
What are the key demand drivers for Coccidiosis Vaccines?
More countries and regions are beginning to implement strict drug residue regulations, which has further driven the use of vaccines as an alternative solution.
Who should buy the Coccidiosis Vaccines market report?
The report is intended for manufacturers and solution providers, distributors and end users in Poultry, Rabbit and Others, investors and consultants, and government or industry bodies who need market size, segmentation, competitive and regional data for the Coccidiosis Vaccines market.
What license options are available for this report?
The report is available as a Single User License (US$ 3,500, one named user), a Site License (US$ 5,250, up to 10 users) and a Global / Corporate License (US$ 7,000, unlimited users), all delivered in PDF format.

Research Methodology

All MarketResearchReports.com strategic research reports follow a rigorous, multi-stage methodology combining AI-assisted data synthesis with expert analyst validation.

01
Secondary Research & Data Aggregation

Systematic collection from 500+ verified sources including SEC filings, industry databases (Bloomberg, Statista, OECD), regulatory filings, trade publications, patent databases, and company annual reports. AI-assisted extraction identifies relevant data points across 10,000+ documents per report.

02
Market Sizing — Bottom-Up & Top-Down

Dual-validation approach: bottom-up sizing aggregates segment-level production, consumption, and trade data; top-down sizing cross-validates against macroeconomic indicators and total addressable market estimates. Discrepancies >5% trigger analyst review.

03
Competitive Intelligence

Company profiles built from public financial disclosures, product launches, M&A activity, job postings (as capability proxies), and supply chain mapping. Market share estimates triangulated across revenue, capacity, and shipment data.

04
Demand Forecasting

CAGR projections use time-series regression on 5-10 years of historical data, adjusted for identified demand drivers (technology adoption curves, regulatory catalysts, demographic shifts) and demand inhibitors (cost barriers, substitution risk). Scenario modeling covers base, optimistic, and conservative cases.

05
Analyst Validation & Quality Assurance

All quantitative outputs reviewed by a domain-specialist analyst before publication. Data triangulation requires minimum 3 independent sources for every key figure. Reports undergo a structured peer review against our 47-point quality checklist covering methodology, data citations, logical consistency, and formatting standards.

06
Continuous Updates

On-demand reports are generated at time of purchase, incorporating the most recent available data. Static reports are republished when underlying market conditions shift by >10% from baseline assumptions. Purchasers receive update notifications for 12 months.

Select a license
from US$3,500.00
Report License Type
Optional add-ons
On demand · delivered within 24-48 hours
Secure checkout · SSL encrypted
License terms included
Post-purchase analyst support
Custom research

Need a customized version?

Get country-, segment- or company-specific intelligence tailored to your exact requirements.

Request custom research →
Talk to a research advisor USA: +1-302-703-9904 India: +91-8762746600
Trusted by

Leading Brands in This Industry

Logos are trademarks of their respective owners and indicate a verified past business relationship, not a current partnership or endorsement.